Drug intelligence / Profile preview

Azlocillin and Gentamicin

Development stage
Unknown
Lead developer
Zhejiang Jinhua CONBA Bio-Pharm
Modality
Small Molecules
Administration
Parenteral, Intravenous
01

Overview

The combination of azlocillin and gentamicin represents a synergistic antibiotic pairing that leverages the complementary mechanisms of both drugs to enhance antimicrobial efficacy. ## Mechanism of Action Azlocillin is an acylampicillin (extended-spectrum penicillin) that works by binding to specific penicillin-binding proteins (PBPs) located inside bacterial cell walls. This binding inhibits the third and final stage of bacterial cell wall synthesis, leading to cell lysis mediated by bacterial autolytic enzymes[3][6]. Azlocillin may also interfere with autolysin inhibitors, further promoting bacterial destruction[3]. Gentamicin, an aminoglycoside, binds to prokaryotic ribosomes, inhibiting protein synthesis in susceptible bacteria. This binding occurs at the 16S rRNA in helix 44 near the A site of the 30S ribosomal subunit, altering critical interactions and displacing important residues. This disruption has multiple negative effects on bacterial function, including inhibition of translation, initiation, elongation, and ribosome recycling[4][5][8]. ## Synergistic Effects The combination of azlocillin and gentamicin demonstrates significant synergistic activity against multiple bacterial pathogens: - **Pseudomonas aeruginosa**: The combined effect is synergistic against many strains of this difficult-to-treat pathogen[1][4][7] - **Staphylococcus aureus**: Synergistic effects are frequently observed[1] - **Enterobacteriaceae**: Enhanced killing is seen against many members of this family[1] - **Enterococcal strains**: While gentamicin combined with penicillins shows synergy against Enterococcus species, specific data on azlocillin-gentamicin for enterococci is limited[4][7] The synergistic effect is typically more pronounced against organisms with low sensitivity to azlocillin and less pronounced against organisms resistant to aminoglycosides[1]. ## Pharmacokinetic Considerations When used together, azlocillin may decrease the serum concentration of gentamicin, potentially affecting dosing requirements[3][5]. This interaction should be considered when administering the combination. ## Clinical Applications This antibiotic combination is particularly valuable for treating: - Serious infections caused by Pseudomonas aeruginosa - Mixed infections involving both gram-positive and gram-negative pathogens - Life-threatening infections where broad-spectrum coverage is needed before culture results are available ## Administration Both medications are administered parenterally, with gentamicin typically given intravenously in hospitalized patients[4]. Dosing should be carefully monitored, particularly for gentamicin, which requires therapeutic drug monitoring to prevent toxicity. ## Limitations It's important to note that there is no general rule to predict with certainty whether this antibiotic combination will act synergistically on a specific bacterial strain[1]. Additionally, bacteria resistant to one aminoglycoside may be resistant to others, potentially limiting effectiveness in some cases[4][8].

02

Targets

30S A-site (Bacterial ribosomal 30S A-site)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Azlocillin and Gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azlocillin and Gentamicin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call